News

Press releases

2023

26 September, 2023 Toleranzia starts toxicology study of its lead drug candidate TOL2 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has started the regulatory GLP-toxicology study of its drug candidate...
15 September, 2023 Toleranzia announces outcome in rights issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG...
28 August, 2023 Toleranzia publishes prospectus in connection with rights issue of units News Corporate Action Prospectus English Regulatory LHFI IR Optional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG...
25 August, 2023 Toleranzia AB: Interim report second quarter 2023 News English Regulatory MAR Report Interim Q2 IR Optional
Three months, April 1 - June 30· Net sales amounted to -- KSEK (--)· Profit after financial items amounted to KSEK -2 503...
24 August, 2023 Toleranzia establishes a freeze-dried formulation of the TOL2 drug product News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has finalized the development of an optimized drug product formulation...
21 August, 2023 Toleranzia runs GMP manufacturing of drug candidate TOL2 for clinical study News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully completed the manufacturing steps of the GMP...
18 August, 2023 Toleranzia carries out a rights issue of units of approximately SEK 55 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG...
7 June, 2023 Announcement from the 2023 Annual General Meeting of Toleranzia AB (publ) News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 7 June 2023. The meeting was conducted with...
9 May, 2023 Notice of Annual General Meeting of Toleranzia AB (publ) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to attend the Annual General...
3 May, 2023 Toleranzia AB: Interim report 2023-01-01 – 2023-03-31 News English Regulatory MAR Report Interim Q1 IR Optional
First quarter, 2023 Three months, January 1 - March 31 · Net sales amounted to -- KSEK (--) · Profit after financial items...
6 April, 2023 Toleranzia AB publishes annual report for the financial year 2022 News English Regulatory Listing Regulation Report Annual IR Optional
Toleranzia AB today publishes its annual report and auditors' report for the financial year 2022. The reports are available on the company's (www.toleranzia.se)...
31 March, 2023 Toleranzia receives funding from Vinnova for ANCA vasculitis project News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") announces today that the Company has been awarded a grant from Vinnova for a project...
30 March, 2023 Toleranzia concludes manufacturing of a technical batch of drug candidate TOL2 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully manufactured a technical batch of TOL2. The...
29 March, 2023 Toleranzia files patent application for tolerogen combination treatments News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has filed a new patent application for the treatment of autoimmune...
24 February, 2023 Toleranzia AB - Year-End Report 2022 News English Regulatory Listing Regulation Report Interim Yearend IR Optional
Fourth quarter 2022 Fourth quarter, 1 October – 31 December · Net sales amounted to -- KSEK (--) · Profit after financial...
12 January, 2023 Toleranzia AB presents Nomination Committee News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023. The Nomination Committee, which has...

2022

27 December, 2022 Toleranzia selects Charles River Laboratories for the GLP toxicology study of its drug candidate TOL2 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) today announces that it has entered into an agreement with Charles River Laboratories (CRL) to conduct the GLP toxicology study on...
1 December, 2022 Toleranzia announces successful large-scale production of drug candidate TOL2 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully manufactured and evaluated a pilot batch of...
28 November, 2022 Statement from the Board of Directors of Toleranzia AB regarding Flerie Invest's mandatory bid News Corporate Action Other English Regulatory Listing Regulation IR Optional
The Board of Directors of Toleranzia AB (publ) ("Toleranzia" or the "Company") recommends that the shareholders of Toleranzia do not...
14 November, 2022 Flerie Invest AB has announced a mandatory bid to the shareholders of Toleranzia AB News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Flerie Invest AB ("Flerie Invest") announced on 2 November 2022 that Flerie Invest has increased its holding in Toleranzia AB ("Toleranzia"...
28 October, 2022 Toleranzia AB: Interim report 2022-01-01 – 2022-09-30 News English Regulatory Listing Regulation Report Interim Q3 IR Optional
Third quarter 2022 Third quarter, 1 July – 30 September · Net sales amounted to -- KSEK (--) · Profit after financial...
26 August, 2022 Toleranzia AB: Interim report 2022-01-01 – 2022-06-30 News English Regulatory Listing Regulation Report Interim Q2 IR Optional
Second quarter 2022 Second quarter, 1 April – 30 June · Net sales 0 SEK (0 SEK). · Profit/loss after financial items...
15 August, 2022 Toleranzia appoints Torbjörn Sannerstedt as new Chief Financial Officer News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has appointed Torbjörn Sannerstedt as its...
3 June, 2022 Announcement from the 2022 Annual General Meeting of Toleranzia AB (publ) News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 3 June 2022. The meeting was conducted with...
3 June, 2022 Positive results for Toleranzia's drug candidate TOL2 published in reputable scientific journal News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the results of preclinical studies with the Company's most...
10 May, 2022 Toleranzia attends international scientific conference on myasthenia gravis in the USA News Corporate Information Other Corporate Information English IR Optional
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that it will participate in The 14th MGFA International Conference...
9 May, 2022 Toleranzia takes part in a research consortium that has been granted support from the Swedish Knowledge Foundation News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Swedish Knowledge Foundation, KKS, has approved an application...
6 May, 2022 Toleranzia AB: Interim Report 2022-01-01 – 2022-03-31 News English Regulatory Listing Regulation Report Interim Q1 IR Optional
First quarter 2022 First quarter, 1 January – 31 March · Net sales 0 SEK (0 SEK). · Profit/loss after financial items...
4 May, 2022 Notice of Annual General Meeting of Toleranzia AB (publ) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to attend the Annual General...
6 April, 2022 Toleranzia AB publishes annual report for the financial year 2021 News English Regulatory Listing Regulation Report Annual IR Optional
Toleranzia AB today publishes its annual report and auditors' report for the financial year 2021. The reports are available on the company's (www.toleranzia.se)...
28 March, 2022 Toleranzia secures access to materials for large-scale manufacturing of drug candidate TOL2 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has taken additional steps to secure access to...

2021

11 November, 2021 Start of Toleranzia's planned clinical trial with TOL2 postponed due to global shortage of certain materials for production of the drug substance News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
Toleranzia AB (publ) today announces that the planned start of a first clinical study of its drug candidate TOL2 in patients with myasthenia gravis will...
10 November, 2021 Toleranzia appoints Ann-Charlotte Rosendahl as Chair of the Board News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) today announces that its Board of Directors has appointed Ann-Charlotte Rosendahl as new Chair of the Board, following the resignation...
21 September, 2021 Toleranzia AB (publ): Receives approximately SEK 42 million through fully subscribed directed share issue News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB (publ) (”Toleranzia” or the ”Company”) today announces the outcome of the directed share issue resolved upon by the...
20 September, 2021 Approximately 95.7 per cent of the warrants of series TO3 were subscribed and Toleranzia AB will receive approximately MSEK 27.5 News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
16 September, 2021 Bulletin from the extraordinary general meeting in Toleranzia AB (publ) on 16 September 2021 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
The extra general meeting in Toleranzia AB (publ), reg. no. 556877-2866 (”Toleranzia” or ”the Company”), was held today on 16 September...
13 September, 2021 The last day for trading in the warrants of series TO3 in Toleranzia AB (publ) is today, 13 September 2021 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Today, 13 September 2021, is the last day for trading in warrants of series TO3 in Toleranzia AB (publ) ("Toleranzia" or the "Company")...
30 August, 2021 The subscription price for the use of warrants of series TO3 in Toleranzia AB has been set at SEK 1.14 and the subscription period will start on 1 September 2021 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
24 August, 2021 Toleranzia announces continued promising results in the production of TOL2 News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
Toleranzia AB ("Toleranzia" or the "Company") has conducted so called “consistency batches” at the contract manufacturer...
10 August, 2021 Notice of extraordinary general meeting of Toleranzia AB (publ) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
The shareholders of Toleranzia AB (publ), org.nr 556877-2866 ("Toleranzia" or the "Company"), are hereby convened to an extraordinary...
9 August, 2021 Toleranzia AB (publ): The board of directors proposes extraordinary general meeting to resolve on a directed share issue of up to circa SEK 42 million and to elect a new board member News Corporate Action Shares Issuance English Regulatory MAR IR Optional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...

Subscribe to Toleranzia’s news here